Cargando…

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft

SIMPLE SUMMARY: Chordomas are rare bone tumors characterized by a high recurrence rate. Presently, no medical treatment is available for advanced diseases due to the lack of molecular data and preclinical models. The current study showed the establishment and characterization of the largest panel ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passeri, Thibault, Dahmani, Ahmed, Masliah-Planchon, Julien, Naguez, Adnan, Michou, Marine, El Botty, Rania, Vacher, Sophie, Bouarich, Rachida, Nicolas, André, Polivka, Marc, Franck, Coralie, Schnitzler, Anne, Némati, Fariba, Roman-Roman, Sergio, Bourdeaut, Franck, Adle-Biassette, Homa, Mammar, Hamid, Froelich, Sébastien, Bièche, Ivan, Decaudin, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946089/ https://www.ncbi.nlm.nih.gov/pubmed/35326637 http://dx.doi.org/10.3390/cancers14061486

Ejemplares similares

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

ATRT-27. COST-EFFECTIVE ASSAYS TO SUBGROUP ATRT IN THE DAILY ROUTINE
por: Lobon-Iglesias, María-Jesús, et al.
Publicado: (2020)

ATRT-11. Anatomico-biological correlations define a new layer for ATRT molecular subgroups pointing to potential lineages of origin
por: Lobon-Iglesias, Maria, et al.
Publicado: (2022)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

MBRS-37. RECURRENT ACTIVATING MUTATIONS OF AKT GENES IN WNT-ACTIVATED MEDULLOBLASTOMAS
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
por: Amelot, Aymeric, et al.
Publicado: (2015)

MBRS-47. RAPID MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA BASED ON DNA METHYLATION BY NANOPORE SEQUENCING
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

High-grade childhood intra-parenchymal brain tumor clustering with ATRT and expanding the cancer spectrum related to inherited SMARCE1 truncating variations
por: Forest, Fabien, et al.
Publicado: (2022)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
por: Euskirchen, Philipp, et al.
Publicado: (2017)

Brain tumor with an ATXN1-NUTM1 fusion gene expands the histologic spectrum of NUTM1-rearranged neoplasia
por: Siegfried, Aurore, et al.
Publicado: (2019)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS
por: Li, Heng, et al.
Publicado: (2022)

Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer
por: Vacher, Sophie, et al.
Publicado: (2020)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target Genes
por: Simeonova, Iva, et al.
Publicado: (2012)

PBRM1 Regulates Stress Response in Epithelial Cells
por: Porter, Elizabeth G., et al.
Publicado: (2019)

A malignant choroid plexus tumour with prevailing immature blastematous elements
por: Tauziède‐Espariat, Arnault, et al.
Publicado: (2021)

Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2021)

Diagnostic accuracy of a minimal immunohistochemical panel in at/rt molecular subtyping, correlated to dna-methylation profiling
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2023)

PBRM1 bromodomains associate with RNA to facilitate chromatin association
por: De Silva, Saumya M, et al.
Publicado: (2023)

Unusually Aggressive Actinic Keratosis of the Eyelid and Conjunctiva
por: AL-HAGE, Jana, et al.
Publicado: (2023)

Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2017)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Role of the Pbrm1 subunit and the PBAF complex in Schwann cell development
por: Polanetzki, Vanessa, et al.
Publicado: (2022)

A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors
por: Liu, Jin, et al.
Publicado: (2022)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
por: Dai, Jiali, et al.
Publicado: (2023)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1hs2dbqq09r81r2l1s3jl236u8